International Journal of Thyroidology

Indexed in /covered by CAS, KoreaScience & DOI/Crossref:eISSN 2466-1899   pISSN 2384-3799

Table. 4.

Table. 4.

Impact of percutaneous ethanol ablation (EA) on systemic disease for patients with and without post-EA radioactive iodine (RAI) treatment

Total No post-EA RAI treatment Post-EA RAI treatment
Number of patientsf 38 22 16
Follow-up, months (mean/range) 40.50 (12-73) 41.76 (12-73) 38.65 (15-62)
TNM stage I or II n (%) 19 (50%) 21 (95.45%) 10 (62.5%)
Patients with ≤2 lesions n (%) 15 (39.47%) 17 (77.27%) 8 (50%)
Patients with TSH-supressed Tg<0.2 ng/mL before EA (n/%) 5 (13.15%) 4 (18.18%) 1 (6.25%)
TSH-supressed Tg before EA, ng/mL (median, interquartile range) 2.75 (1.3-9.35) 1.61 (0.69-4.02) 4.34 (2.3-14.48)*
TSH-stimulated Tg before EA, ng/mL (median, interquartile range) 28.28 (6.54-71.0) 11.9 (2.82-37.4) 50.84 (13.83-97.7)*
TSH-supressed Tg after EA, ng/mL (median, interquartile range) 0.85 (0-8.06) 0.77 (0.12-4.3) 1.43 (0.10-8.1)*
TSH-stimulated Tg after EA, ng/mL (median, interquartile range) (n)α 11.86 (1.13-30.6) (20) 1.13 (0.93-2.82) (4) 14.68 (1.13-36.33) (16)
Time (months) from EA to RAI/hrTSH (mean±SD) 6.38±5.22 6.15±4.74 6.72±5.83
Patients with TSH-supressed Tg<0.2 ng/mL (n/%) 17/38 (44.73%) 10/22 (45.45%) 7/16 (43.75%)
Patients with TSH-stimulated Tg<1 ng/mL (n/%) 6/20 (30%) 2/4 (50%) 4/16 (25%)

hrTSH: human recombinant TSH stimulation test, SD: standard deviation

fPatients with positive thyroglobulin antibodies (4) were excluded.

RAI: Radioactive iodine. α=p not significant. β=p<0.05 (comparison between both groups)

αOnly four patients underwent hrTSH-stimulated Tg determination without RAI treatment.

*p<0.05 (two-sided t-Student)

Int J Thyroidol 2020;13:128-41 https://doi.org/10.11106/ijt.2020.13.2.128
© 2020 Int J Thyroidol